Drug-induced organ toxicity is still a persistent challenge for drug developers. Adverse effects on major organs account for a substantial share of clinical trial failures and post-market therapeutic withdrawals. Standard hepatic injury markers like alanine aminotransferase show inadequate diagnostic sensitivity and fail to predict early systemic damage.
Conventional cellular markers cannot reliably detect liver damage before significant organ damage occurs. Serum enzymes can come from multiple cell types and often appear only after injury has begun. This makes it difficult to distinguish early, treatable injury from more serious damage — and can lead drug developers to discard promising drug candidates.
Tagomics has launched a commercial platform to resolve diagnostic specificity gaps using a single blood draw. The company designed the LiquiPath offering to analyze tissue-specific methylation patterns in circulating cell-free DNA. This diagnostic technology identifies organs experiencing treatment-related damage before conventional testing markers register a signal.
How do dying cells reveal their epigenetic origin?
Dying cells release fragments into circulation that carry unique epigenetic signatures from their source tissues. Elevated levels of tissue-specific nucleic acids indicate increased cellular turnover and signal potential therapy-induced toxicity. Researchers use CpG methylation patterns to quantitatively assign origin information with higher precision than fragmentomic analysis.
Identifying collateral tissue damage
Determining the origins of circulating fragments provides critical insights into collateral damage affecting genetically normal tissues. Tagomics built the underlying Activace sequencing technology to operationalize early damage detection at a commercial scale. The workflow enriches unmethylated DNA and successfully analyzes highly degraded liquid biopsy samples containing minimal input quantities.
The liquid pathology system layers proprietary cell-type-specific methylation atlases onto a foundational enzymatic sequencing readout. Advanced deconvolution algorithms subsequently attribute collected DNA signals to individual biological sources. A single assay ultimately answers clinical questions regarding the precise location and timing of organ injuries.
What drug development phases does the platform target?
The diagnostic technology monitors toxicity across three distinct phases of the pharmaceutical pipeline to capture early injury events. The platform addresses specific bottlenecks throughout the therapeutic development lifecycle:
- Preclinical studies: Multi-species injury detection supports pharmaceutical commitments regarding animal use reduction.
- Clinical integration: Subclinical toxicity identification occurs before patients develop severe symptoms or breach conventional alarm thresholds.
- Post-marketing surveillance: Ongoing applications provide minimally invasive organ health tracking for patient populations receiving approved therapies.
"Drug safety monitoring has remained largely unchanged for decades, with many current tools detecting damage only after it has occurred," said Jack Kennefick, CEO of Tagomics. "By reading tissue-specific cell-free DNA signals in blood, we believe the platform can help drug developers detect toxicity earlier and understand where injury is occurring," Kennefick said. "These insights are intended to support faster and better-informed decisions."
Competitive landscape for multi-organ safety tests
No blood-based multi-organ toxicity monitoring test has achieved routine clinical adoption despite considerable commercial attention. A recent industry review evaluating the clinical integration of cell-free DNA for drug safety monitoring identified off-target toxicity scenarios as the most tractable initial applications for these emerging technologies. Early adoption will likely focus on targeted scenarios, as monitoring antibody-drug conjugate induced lung disease provides a tractable starting point.
| Approach | Tissue specificity | Detection timing | Multi-organ capability | Species transferability | Setting |
|---|---|---|---|---|---|
ALT/AST | Low | Post-injury | No | Yes | Clinical |
Serum creatinine | Low to moderate | Post-injury | No | Partial | Clinical and preclinical |
miR-122 | Liver-specific | Earlier than ALT | No | Limited | Investigational |
CpG methylation | High | Pre-symptomatic | Yes | Varies | Research |
LiquiPath | High | Pre-symptomatic | Yes | Multi-species | Preclinical and clinical |
Addressing the diagnostic specificity challenge
Traditional markers of kidney function exhibit well-documented limitations regarding both sensitivity and diagnostic specificity. Investigational candidates improve early detection rates; however, they remain completely confined to single organ systems. Resolving multiple organ signals simultaneously across species represents a meaningful advance in translational safety capabilities.
How do blood assays support animal reduction frameworks?
Emerging diagnostic tests generate tissue-specific injury signals without requiring subject sacrifice or extensive cohort expansions. Regulators consider microscopic examination of sacrificed animal tissue the gold standard for confirming nonclinical organ injury. The pharmaceutical sector currently faces growing regulatory pressure to reduce animal testing dependencies under the replacement, reduction, and refinement framework.
Non-invasive monitoring accelerates essential decisions on early-stage therapeutic candidates while producing highly translatable cross-species data. AstraZeneca recently partnered with Tagomics to validate this liquid pathology approach across various drug classes and development stages. Modernization initiatives actively encourage the implementation of these non-terminal evaluation methods to refine global toxicology programs.
Reference atlases dictate deconvolution accuracy
The performance accuracy of any origin system depends entirely on the underlying reference methylation atlas. Tagomics utilizes proprietary databases to train advanced deconvolution algorithms that differentiate overlapping epigenetic signatures in plasma. Foundational research previously validated this enzymatic enrichment strategy using low concentration samples from colorectal cancer cohorts.
Expanding beyond oncology diagnostics
The commercial launch coincides with a strategic corporate expansion moving beyond localized cancer detection applications. Pharmaceutical partners in the early access program actively shape validated use cases and prioritize specific therapeutic modalities. The safety monitoring field is steadily transitioning from single organ proofs of concept toward comprehensive systemic tracking.
Summary of cfDNA safety monitoring
Drug developers require advanced diagnostic tools to identify early organ toxicity before irreversible physiological damage occurs. Analyzing specific methylation patterns in circulating cell-free DNA precisely localizes cellular injury across multiple biological systems. Implementing non-invasive blood tests across the therapeutic pipeline reduces animal testing reliance and accelerates safety decision making.
This article is based on a press release issued by Tagomics and was produced under Drug Discovery News' AI Editorial Guidelines.
